Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Wendall Wierenga sold 20,000 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $38.46, for a total value of $769,200.00. Following the transaction, the director now directly owns 24,848 shares of the company's stock, valued at approximately $955,654.08. The trade was a 44.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Cytokinetics Trading Up 0.2 %
CYTK traded up $0.10 during trading on Friday, reaching $40.43. 893,391 shares of the stock traded hands, compared to its average volume of 1,611,927. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. The stock's 50-day moving average is $42.09 and its 200 day moving average is $47.15. Cytokinetics, Incorporated has a 12 month low of $32.74 and a 12 month high of $68.44. The stock has a market capitalization of $4.82 billion, a PE ratio of -7.51 and a beta of 0.94.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.29) by $0.03. The company had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.26 million. Equities analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Hedge Funds Weigh In On Cytokinetics
Several institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp increased its position in Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 374 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Cytokinetics during the fourth quarter valued at approximately $29,000. Fifth Third Bancorp increased its holdings in shares of Cytokinetics by 42.2% during the first quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 291 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 916 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Cytokinetics by 281.0% in the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 826 shares in the last quarter.
Analysts Set New Price Targets
A number of analysts have weighed in on CYTK shares. Needham & Company LLC reaffirmed a "buy" rating and set a $72.00 target price on shares of Cytokinetics in a research note on Tuesday, April 8th. JMP Securities reaffirmed a "market outperform" rating and issued a $78.00 target price on shares of Cytokinetics in a report on Thursday, April 10th. Morgan Stanley set a $67.00 price target on Cytokinetics in a research note on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $120.00 price objective on shares of Cytokinetics in a research note on Monday, April 21st. Finally, Barclays initiated coverage on shares of Cytokinetics in a research report on Thursday. They set an "overweight" rating and a $55.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Cytokinetics has a consensus rating of "Moderate Buy" and a consensus price target of $79.13.
Read Our Latest Stock Report on Cytokinetics
About Cytokinetics
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Further Reading
Before you consider Cytokinetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.
While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
